BULLFROG AI HOLDINGS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 6th, 2024 • BullFrog AI Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 6th, 2024 Company Industry JurisdictionBULLFROG AI HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”), an aggregate of 1,507,139 shares (each, a “Firm Share” and in aggregate, the “Firm Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”) (or pre-funded warrants (each, a “Firm Pre-Funded Warrant,” and in the aggregate, the “Firm Pre-Funded Warrants”) to purchase one share of Common Stock (the “Firm Pre-Funded Warrant Shares”) at an exercise price of $0.001 per share of Common Stock until such time as the Pre- Funded Warrant is exercised in full, subject to adjustment as provided in the Pre-Funded Warrant in lieu thereof), and an aggregate of 1,507,139 warrants (each, a “Firm Warrant,” and in the aggregate, the “Firm Warrants”)
UNDERWRITING AGREEMENT 5,260,901 Units, Each Consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock; and 999,076 Pre- Funded Units, Each Consisting of One Pre-Funded Warrant to Purchase One Share of Common Stock...Underwriting Agreement • February 2nd, 2024 • 60 Degrees Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 2nd, 2024 Company Industry JurisdictionAn aggregate of 5,260,901 Units (the “Firm Units”), each Firm Unit consisting of: (i) one share of the Company’s common stock, $0.0001 par value per share (the “Common Shares”); and (ii) one non-tradeable warrant to purchase one share of Common Stock (the “Non-Tradeable Warrants”); and
BULLFROG AI HOLDINGS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • January 29th, 2024 • BullFrog AI Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 29th, 2024 Company Industry JurisdictionBULLFROG AI HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”), an aggregate of [ ] shares (each, a “Firm Share” and in aggregate, the “Firm Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”), an aggregate of [ ] pre-funded warrants (each, a “Firm Pre-Funded Warrant,” and in the aggregate, the “Firm Pre-Funded Warrants”) to purchase one share of Common Stock (the “Firm Pre-Funded Warrant Shares”) at an exercise price of $[ ] until such time as the Pre-Funded Warrant is exercised in full, subject to adjustment as provided in the Pre-Funded Warrant, and an aggregate of [ ] warrants (each, a “Firm Warrant,” and in the aggregate, the “Firm Warrants”) to purchase one share of Common Stock (th
UNDERWRITING AGREEMENT 1,415,095 Units, Each Consisting of One Share of Common Stock, One Warrant to Purchase One Share of Common Stock, and One Non-tradeable Warrant to Purchase One Share of Common StockUnderwriting Agreement • July 17th, 2023 • 60 Degrees Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 17th, 2023 Company Industry JurisdictionIn addition, the Company shall pay the Representative an aggregate cash discount equal to eight percent (8%) of the aggregate sales price of securities sold in the Offering plus one and one-half percent (1.5%) of the aggregate sales price of securities sold in the Offering. In addition, the Company shall issue to the Representative that number of warrants equal to six percent (6%) of the number of securities of common stock sold in the Offering.
BULLFROG AI HOLDINGS, INC. UNDERWRITING AGREEMENT 1,317,647 Units, Each Consisting of One Share of Common Stock, One Warrant to Purchase One Share of Common Stock, and One Non-tradeable Warrant to Purchase One Share of Common StockUnderwriting Agreement • January 10th, 2023 • BullFrog AI Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 10th, 2023 Company Industry JurisdictionBULLFROG AI HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”), an aggregate of 1,317,647 Units (the “Firm Units”), each Firm Unit consisting of: (i) one share of the Company’s common stock, $0.00001 par value per share (the “Common Stock”); (ii) one tradeable warrant to purchase one share of Common Stock (the “Firm Tradeable Warrants”); and, one non-tradeable warrant the “Firm Non-tradeable Warrants” and together with the Firm Tradeable Warrants, the “Firm Warrants”). The 1,317,647 shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” together with the Firm Units and the Firm Warrants, the “Firm Securities.” The Firm Warrants shall be issued pursuant to and shall have the rights
BULLFROG AI HOLDINGS, INC. UNDERWRITING AGREEMENT [*] Units Consisting of [*] Shares of Common Stock, And Warrants to Purchase [*] Shares of Common StockUnderwriting Agreement • October 19th, 2022 • BullFrog AI Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 19th, 2022 Company Industry JurisdictionBULLFROG AI HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”), an aggregate of [*] Units (the “Firm Units”), each Firm Unit consisting of: (i) one share of the Company’s common stock, $0.00001 par value per share (the “Common Stock”); (ii) one warrant to purchase one share of Common Stock (the “Purchase Warrants”). The [*] shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Purchase Warrants to purchase [*] shares of Common Stock are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to and shall have the rights and privileges set forth in, a warrant agen
GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT ____________ Shares of Common StockUnderwriting Agreement • December 15th, 2020 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 15th, 2020 Company Industry JurisdictionGREENWICH LIFESCIENCES, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Aegis Capital Corp. is acting as representative (the “Representative”), an aggregate of ____________ authorized but unissued shares of common stock, par value $0.001 per share, (the “Common Stock”) of the Company (the “Firm Shares”). The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, up to an additional ____________ shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares” or the “Securities”.
Phio Pharmaceuticals Corp. 993,633 Shares of Common Stock Pre-Funded Warrants to Purchase 1,006,367 Shares of Common Stock and Warrants to Purchase 2,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 13th, 2020 • Phio Pharmaceuticals Corp. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 13th, 2020 Company Industry JurisdictionPhio Pharmaceuticals Corp., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) 993,633 shares of common stock (the “Firm Shares”), par value $0.0001 per share, of the Company (the “Common Stock”) and (b) 1,006,367 pre-funded warrants to purchase 1,006,367 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”); and (ii) 2,000,000 warrants to purchase 2,000,000 shares of Common Stock (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by each Underwriter is set forth opposite its name on Schedule A hereto. The Company also proposes to sell to each Underwriter, at the option of the Underwriter, up to an additional 300,000 shares of Common Stock (the “Option Shares”) and/or warrants to pur